PHIO News and Press, Phio Pharmaceuticals Corp. From 05/16/23

Phio Pharmaceuticals Announces FDA Clearance to Initiate Clinical Trial of PH-762 for Treatment of Skin Carcinomas PR Newswire MARLBOROUGH, Mass. , May 16, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company...

2023-05-11 17:28:47 ET Phio Pharmaceuticals press release ( NASDAQ: PHIO ): Q1 GAAP EPS of -$3.15. At March 31, 2023, the Company had cash of $9.0 million as compared with $11.8 million at December 31, 2022. For further details see: Phio Pharmaceuticals GAAP EPS ...

Phio Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update PR Newswire MARLBOROUGH, Mass. , May 11, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASY...

Phio Pharmaceuticals Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PR Newswire MARLBOROUGH, Mass. , April 20, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology compa...

2023-04-19 10:05:08 ET Gainers: Vyne Therapeutics ( VYNE ) +32% . Ensysce Biosciences ( ENSC ) +23% . Legend Biotech ( LEGN ) +20% . Tempest Therapeutics ( TPST ) +16% . Evoke Pharma ( EVOK ) +14% . Losers: Allarity T...

Phio Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PR Newswire MARLBOROUGH, Mass. , April 18, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose pr...

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is one of today's top gainers. The company's shares are currently up 50.66% on the day to $9.16. Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor an...

Phio Pharmaceuticals Presents Preclinical Data Demonstrating Synergy-Enhanced in vivo Anti-Tumor Efficacy of PD-1/CTLA-4 Dual-Targeting INTASYL PR Newswire - Data to be presented at American Association for Cancer Research (AACR) Annual Meeting 2023 - MARLBOROUGH, Ma...

2023-04-17 11:02:23 ET Phio Pharmaceuticals ( NASDAQ: PHIO ) is trading ~11% higher after it said a preclinical study showed that intratumoral administration of its drug, mPH-762, stimulated a local anti-tumor immune response and generated systemic tumor-reactive memory T cell...

Phio Pharmaceuticals Presents Preclinical Study Showing PH-762 Induces Systemic Memory T Cell Mediators of Anti-Tumor Immunity PR Newswire - Data to be presented at American Association for Cancer Research (AACR) Annual Meeting 2023 - MARLBOROUGH, Mass. , Apr...